anti-CD147 CAR NK-cell therapy (Protheragen)

N/A

Report date: 2025/03/14 16:48:38

Base Information

Drug Nameanti-CD147 CAR NK-cell therapy (Protheragen)

Drug Alias Nameanti-CD147 CAR NK-cell therapy (Rutgers University)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionBasigin modulators

TargetsBasigin

Therapy Area/IndicationsSolid tumoursCarcinoma, Hepatocellular

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesRutgers University

China Registration ClassN/A

Develop Information

Active CompaniesProtheragen Inc

Inactive CompaniesRutgers University

Active IndicationsSolid tumoursCarcinoma, Hepatocellular

Inactive IndicationsN/A

Other Information

ATC CodeN/A